INHIBITION OF TYPE-A AND TYPE-B MONOAMINE-OXIDASE BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE
- 1 January 1985
- journal article
- research article
- Vol. 232 (3) , 696-701
Abstract
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was studied as an inhibitor of type A monoamine oxidase (MAO) acting on [14C]serotonin as substrate and of type B MAO acting on [14C]phenylethylamine as substrate. MPTP was a reasonably potent (Ki = 9 .mu.M), competitive, reversible inhibitor of MAO-A from rat brain in vitro. MPTP given at a 30 mg/kg i.p. dose antagonized the irreversible inactivation of MAO-A in rat brain by pargyline, indicating that it inhibited MAO-A in vivo. At that same dose, MPTP prevented the conversion of dopamine released by Ro 4-1284 [2-ethyl-2,3,4,6,7,11b-hexa-hydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]-quinolizin-2-ol HCl] to 3,4-dihydroxyphenylacetic acid and attenuated its conversion to homovanillic acid. Because dopamine is mainly deaminated by MAO-A, at least in rodent brain, inhibition of MAO-A by MPTP might play some part in its production of persistent effects on striatal dopamine neurons such as protection of intraneuronal, extragranular dopamine from deamination. MPTP was less potent as an inhibitor by MAO-B from rat brain in vitro (Ki = 106 .mu.M). In contrast to the inhibition of MAO-A, the inhibition of MAO-B by MPTP showed noncompetitive kinetics, was not fully reversible by dialysis and was time dependent. The characteristics of MAO-B inhibition are like those of a kcat inhibitor, which is acted upon by an enzyme to produce a reactive product that can covalently attach to the enzyme or other macromolecules. Although little inactivation of MAO-B was found in rat brain in vivo after MPTP injection, the possibility that a product or products of MAO-B action on MPTP may contribute to the persistent effects of MPTP on striatal dopamine neurons suggests a 2nd way in which interaction between MPTP and MAO might be important in the in vivo actions of MPTP. Because MPTP apparently causes irreversible Parkinson''s disease in humans and a Parkinsonian-like syndrome in monkeys associated with neurotoxic effects on striatal dopamine neurons, a more complete understanding of its actions on dopamine neurons is urgently needed. Interactions of MPTP with MAO-A and with MAO-B can be considered as such research progresses.This publication has 24 references indexed in Scilit:
- Monoamine Oxidases A and B as Components of a Membrane ComplexJournal of Neurochemistry, 1982
- Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: Time course and time-dependent interactions with amfonelic acidBrain Research, 1982
- Type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in ratsBiochemical Pharmacology, 1981
- Specificity of Endogenous Substrates for Types A and B Monoamine Oxidase in Rat StriatumJournal of Neurochemistry, 1981
- Studies on the subcellular localization of monoamine oxidase types A and B and its importance for the deamination of dopamine in the rat brainBiochemical Pharmacology, 1980
- Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivoJournal of Pharmacy and Pharmacology, 1978
- Preferential deamination of dopamine by an A type monoamine oxidase in rat brainNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1976
- Depression of Norepinephrine and 5-Hydroxytryptamine in the Brain by Benzoquinolizine DerivativesScience, 1959
- Antagonism between harmaline and long-acting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brainCellular and Molecular Life Sciences, 1959